Table 3.
Adherence to CAD Performance Measures Between Patients With STEMI Receiving Fibrinolysis vs PPCI
| Performance Measure | Fibrinolytics N=2441 (%) | Primary PCI n=26 749 (%) | P Value |
|---|---|---|---|
| ACE‐I or ARB for LVSD | 342 (83.2) | 4440 (90.2) | <0.0001 |
| Aspirin at discharge | 2175 (97.0) | 24 685 (98.6) | <0.0001 |
| Aspirin within 24 hours | 1510 (93.5) | 17 707 (96.7) | <0.0001 |
| Β‐Βlockers at discharge | 2061 (95.0) | 23 616 (97.9) | <0.0001 |
| Patients with LDL‐C >100 mg/dL who received statins or lipid‐lowering drugs | 783 (90.2) | 9090 (95.3) | <0.0001 |
| Smoking cessation for CAD | 980 (88.9) | 10 773 (94.7) | <0.0001 |
| Defect‐free care (100% compliance with performance measures) | 1932 (81.1) | 23 631 (90.1) | <0.0001 |
ACE‐I indicates angiotensin‐converting enzyme inhibitor; ARB, angiotensin receptor blocker; CAD, coronary artery disease; LDL, low‐density lipoprotein; LVSD, left ventricular systolic dysfunction; PPCI, primary percutaneous coronary intervention; STEMI, ST elevation myocardial infarction.